MELINTA THERAPEUTICS, INC. /NEW/
MELINTA THERAPEUTICS, INC. /NEW/ (MLNT): 7 pipeline candidates · ~9 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.4 months
D/E -4.77 · 0% dilution
Lead: Approved
7 candidates
N/A
N/A
A transparent, data-derived signal for MELINTA THERAPEUTICS, INC. /NEW/across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$63.7M
Quarterly Burn
$26.8M
Runway
9.4 mo
Revenue
$15.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| antibiotics | Phase 2 |
| baxdela | Approved |
| meropenem-vaborbactam | Phase 2 |
| minocin | Approved |
| orbactiv | Approved |
| radezolid | Preclinical |
| vabomere | Phase 2 |
Frequently asked questions
How many drug candidates are in MELINTA THERAPEUTICS, INC. /NEW/'s pipeline?
MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MELINTA THERAPEUTICS, INC. /NEW/'s lead drug candidate?
MELINTA THERAPEUTICS, INC. /NEW/'s most advanced tracked candidate is antibiotics (Phase 2) for Acute Pyelonephritis.
What is MELINTA THERAPEUTICS, INC. /NEW/'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MELINTA THERAPEUTICS, INC. /NEW/ has approximately 9.4 months of cash runway.
Who is the CEO of MELINTA THERAPEUTICS, INC. /NEW/?
Dova Pharmaceuticals Inc is the chief executive officer of MELINTA THERAPEUTICS, INC. /NEW/ (MLNT).
Get the full picture on MELINTA THERAPEUTICS, INC. /NEW/
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.